These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38377526)

  • 21. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT.
    Wang X; Wang C; Zhang Y; An Z
    BMC Psychiatry; 2023 May; 23(1):334. PubMed ID: 37173736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial.
    Dunlop BW; Parikh SV; Rothschild AJ; Thase ME; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC; Macaluso M; Logan J; Traxler P; Li J; Johnson H; Greden JF
    BMC Psychiatry; 2019 Dec; 19(1):420. PubMed ID: 31881956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review.
    Meaddough EL; Sarasua SM; Fasolino TK; Farrell CL
    Pharmacogenomics J; 2021 Aug; 21(4):409-422. PubMed ID: 34140647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic.
    Claudio-Campos K; Padrón A; Jerkins G; Nainaparampil J; Nelson R; Martin A; Wiisanen K; Smith DM; Strekalova Y; Marsiske M; Cicali EJ; Cavallari LH; Mathews CA
    Clin Transl Sci; 2021 Mar; 14(2):589-598. PubMed ID: 33166056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis.
    Brown L; Vranjkovic O; Li J; Yu K; Al Habbab T; Johnson H; Brown K; Jablonski MR; Dechairo B
    Pharmacogenomics; 2020 Jun; 21(8):559-569. PubMed ID: 32301649
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.
    Tiwari AK; Zai CC; Altar CA; Tanner JA; Davies PE; Traxler P; Li J; Cogan ES; Kucera MT; Gugila A; Braganza N; Emmerson H; Zai G; Müller DJ; Levitan R; Kloiber S; Daskalakis ZJ; Frey BN; Bowen JM; Tarride JE; Tytus R; Chandrasena R; Voudouris N; Taylor VH; Tempier R; Sharma V; Vasudev A; Dzongowski P; Pliamm L; Greenspoon T; Dechairo BM; Kennedy JL
    Transl Psychiatry; 2022 Mar; 12(1):101. PubMed ID: 35288545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetic testing in psychiatric inpatients with polypharmacy is associated with decreased medication side effects but not via medication changes.
    Collins AR; Kung S; Ho JT; Wright JA; Dammen KC; Johnson EK; Lapid MI; Leung JG
    J Psychiatr Res; 2020 Jul; 126():105-111. PubMed ID: 32442780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetic testing in primary care could bolster depression treatment: A value proposition.
    Sperber NR; Roberts MC; Gonzales S; Bendz LM; Cragun D; Haga SB; Wu RR; Omeogu C; Kaufman B; Petry NJ; Ramsey LB; Uber R
    Clin Transl Sci; 2024 Jun; 17(6):e13837. PubMed ID: 38898561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders.
    Blasco-Fontecilla H
    J Neural Transm (Vienna); 2019 Jan; 126(1):101-107. PubMed ID: 29626260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial.
    Elliott LS; Henderson JC; Neradilek MB; Moyer NA; Ashcraft KC; Thirumaran RK
    PLoS One; 2017; 12(2):e0170905. PubMed ID: 28151991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective.
    Carta A; Del Zompo M; Meloni A; Mola F; Paribello P; Pinna F; Pinna M; Pisanu C; Manchia M; Squassina A; Carpiniello B; Conversano C
    Clin Drug Investig; 2022 Sep; 42(9):733-746. PubMed ID: 35930170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study.
    Ramsey CM; Lynch KG; Thase ME; Gelernter J; Kranzler HR; Pyne JM; Shih MC; Stone A; ; Oslin DW
    J Affect Disord; 2021 Mar; 282():1272-1277. PubMed ID: 33601706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smartphone Cognitive Behavioral Therapy as an Adjunct to Pharmacotherapy for Refractory Depression: Randomized Controlled Trial.
    Mantani A; Kato T; Furukawa TA; Horikoshi M; Imai H; Hiroe T; Chino B; Funayama T; Yonemoto N; Zhou Q; Kawanishi N
    J Med Internet Res; 2017 Nov; 19(11):e373. PubMed ID: 29101095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetic Testing in a 70-Year-Old Woman with Polypharmacy and Multiple Comorbidities: A Case Report.
    Jessop JP; Russell J; DeJesus A; Bardolia C; Hanna A; Turgeon J; Michaud V; Amin NS
    Am J Case Rep; 2023 Feb; 24():e938850. PubMed ID: 36804920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.
    Greden JF; Parikh SV; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC; Macaluso M; Li J; Brown K; Gilbert A; Burns L; Jablonski MR; Dechairo B
    J Psychiatr Res; 2019 Apr; 111():59-67. PubMed ID: 30677646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.
    Duffy L; Clarke CS; Lewis G; Marston L; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Mangin D; Moore M; Nazareth I; Wiles N; Bacon F; Bird M; Brabyn S; Burns A; Donkor Y; Hunt A; Pervin J; Lewis G
    Health Technol Assess; 2021 Nov; 25(69):1-62. PubMed ID: 34842135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial.
    Papastergiou J; Quilty LC; Li W; Thiruchselvam T; Jain E; Gove P; Mandlsohn L; van den Bemt B; Pojskic N
    Clin Transl Sci; 2021 Jul; 14(4):1359-1368. PubMed ID: 33641259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care.
    Saya S; Chondros P; Abela A; Mihalopolous C; Chatterton ML; Gunn J; Chen TF; Polasek TM; Dettmann E; Brooks R; King M; Spencer L; Alphonse P; Milton S; Ramsay G; Siviour Z; Liew J; Ly P; Thoenig M; Seychell R; La Rocca F; Hesson LB; Mejias N; Sivertsen T; Galea MA; Bousman C; Emery J
    Trials; 2023 May; 24(1):342. PubMed ID: 37208772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.